跳至主要内容
临床试验/NCT03557671
NCT03557671已完成不适用

Evaluation of the Hypoallergenicity of a New Formula Based on Hydrolyzed Rice Proteins (TRHF 2017) in Children With Confirmed Immunoglobulin E (IgE) or Non-immunoglobulin E-mediated Cow's Milk Allergy (CMA)

United Pharmaceuticals5 个研究点 分布在 3 个国家目标入组 72 人开始时间: 2018年8月23日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
72
试验地点
5
主要终点
hypoallergenicity

研究概览

简要总结

The aim of this study is to show the hypoallergenicity of a new thickened rice based formula (TRHF) through a double blind placebo controlled food challenge (DBPCFC), as recommended by the American Academy of Pediatrics, in subjects with IgE-mediated CMA and in subjects with non-IgE-mediated CMA.

详细描述

The study is made of 2 different steps : 1st step is a double blind randomised food challenge where the new formula is compared to a placebo.

The second part of the trial consists in an open phase during which all infants will be fed with the study formula.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
1 Month 至 36 Months(Child)
性别
All
接受健康志愿者

入选标准

  • with suspected CMA or with a CMA diagnosed by a DBPCFC performed in the last 2 months prior to inclusion
  • free of clinical allergic symptoms for at least one week (i.e. successfully fed an elimination diet);
  • whose parents signed the informed consent

排除标准

  • mainly breast fed, drinking less than 250ml of formula/day, presenting any situation, which, according to the investigator, may interfere with the study participation or lead to a particular risk for the subject

结局指标

主要结局

hypoallergenicity

时间窗: 7 days

the percentage of children tolerating the formula during the double blind placebo controlled food challenge (TRHF 2017 vs. placebo formula).

次要结局

  • Regurgitations(1, 2, 3, 4, 5 and 6 months)
  • Vomiting(1, 2, 3, 4, 5 and 6 months)
  • Bloating and gas(1, 2, 3, 4, 5 and 6 months)
  • Sleeping time over 24h satisfaction(1, 2, 3, 4, 5 and 6 months)
  • Unexplained crying(1, 2, 3, 4, 5 and 6 months)
  • Height(1, 2, 3, 4, 5 and 6 months)
  • BMI(1, 2, 3, 4, 5 and 6 months)
  • Stool consistency(1, 2, 3, 4, 5 and 6 months)
  • Stool frequency(1, 2, 3, 4, 5 and 6 months)
  • Respiratory symptoms(1, 2, 3, 4, 5 and 6 months)
  • Urticaria(1, 2, 3, 4, 5 and 6 months)
  • Angioedema(1, 2, 3, 4, 5 and 6 months)
  • Abdominal pain(1, 2, 3, 4, 5 and 6 months)
  • Weight(1, 2, 3, 4, 5 and 6 months)
  • Blood in stools(1, 2, 3, 4, 5 and 6 months)
  • Head circumference(1, 2, 3, 4, 5 and 6 months)
  • Eczema(1, 2, 3, 4, 5 and 6 months)
  • Number of patients with treatment emergent Adverse Events(1, 2, 3, 4, 5 and 6 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验